
A study published in JAMA Network Open examined 1.6 million type 2 diabetes patients' medical records and found that those on GLP-1 treatments, like Ozempic, had a significantly lower risk of developing 10 types of obesity-related cancers compared to those on insulin. The study, covering data from March 2005 to November 2018, highlights the potential cancer-preventive benefits of GLP-1 drugs, although further research is needed.
Like
Save
Share